Assessing the risk of ovarian malignancy in asymptomatic women with abnormal CA 125 and transvaginal ultrasound scans in the prostate, lung, colorectal, and ovarian screening trial

Obstetrics and Gynecology

Volumn 121, Issue 1, 2013, Pages 25-31

  Partridge, Edward E ^a   Greenlee, Robert T ^b   Riley, Thomas L ^b   Commins, John ^b   Ragard, Lawrence ^b   Xu, Jian Lun ^b   Buys, Saundra S ^b   Prorok, Philip C ^b   Fouad, Mona N ^b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b not available

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN;

ADULT; ARTICLE; CANCER RISK; CANCER SCREENING; CANCER SIZE; COHORT ANALYSIS; COLON; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HIGH RISK PATIENT; HUMAN; LUNG; MAJOR CLINICAL STUDY; OVARY; OVARY CANCER; OVARY CYST; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE; RECTUM; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TRANSVAGINAL ECHOGRAPHY;

EID: 84872110263     PISSN: 00297844     EISSN: 1873233X     Source Type: Journal    
DOI: 10.1097/AOG.0b013e3182755e14     Document Type: Article

References (24)

1. Siegel R, Ward E, Brawley O, Jemal A. Cancer Statistics 2011, the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J 2011;5:212-36.
2. Gohagan JK, Prorok PC, Hayes RB, Kramer BS; PLCO Project Team. The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status. Control Clin Trials 2000;21: 251S-72S.
3. Buys SS, Partridge EE, Greene MH, Prorok PC, Reding D, Riley TL, et al.; PLCO Project Team. Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial. Am J Obstet Gynecol 2005;193:1630-9.
4. Partridge EE, Kreimer AR, Greenlee RT, Williams C, Xu JL, Church TR, et al.; PLCO Project Team. Results from four rounds of ovarian cancer screening in a randomized trial. Obstet Gynecol 2009;113:775-82.
5. Buys SS, Partridge EE, Black A, Johnson CC, Lamerato L, Isaacs C, et al.; PLCO Project Team. Effect of screening on ovarian cancer mortality, the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening randomized controlled trial. JAMA 2011;305:2295-303.
6. Weiss NS. Clinical epidemiology: the study of the outcome of illness. 2nd ed. New York (NY): Oxford University Press; 1996:10-11.
7. Jacobs I, Stabile I, Bridges J, Kemsley P, Reynolds C, Grudzinskas J, et al. Multimodal approach to screening for ovarian cancer. Lancet 1988:1:268-71.
8. Baldwin LM, Trivers KF, Matthews B, Andrilla CH, Miller JW, Berry DL, et al. Vignette-based study of ovarian cancer screening: do U.S. physicians report adhering to evidence-based recommendations? Ann Intern Med 2012;156:182-94.
9. Maggino T, Gadduci A, D'Addario V, Pecorelli S, Lissoni A, Stella M, et al. Prospective multicenter study on CA 125 in postmenopausal pelvic masses. Gynecol Oncol 1994;54:117-23.
10. Schutter EM, Kenemans P, Sohn C, Kristen P, Crombach G, Westermann R, et al. Diagnostic value of pelvic examination, ultrasound, and serum CA 125 in postmenopausal women with a pelvic mass. An international multicenter study. Cancer 1994; 74:1398-406.
11. Schutter EM, Sohn C, Kirsten P, Mobus V, Crombach G, Kaufmann M, et al. Estimation of probability of malignancy using a logistic model combining physical examination, ultrasound, serum CA 125, and serum CA 72-4 in postmenopausal women with a pelvic mass: an international multicenter study. Gynecol Oncol 1998;69:56-63.
12. Adonakis GL, Paraskevaidis E, Tsiga S, Seferiadis K, Lolis DE. A combined approach for the early detection of ovarian cancer in asymptomatic women. Eur J Obstet Gynecol Reprod Biol 1996;65:221-5.
13. Dearking AC, Aletti GD, McGee ME, Weaver AL, Sommerfield MK, Cliby WA. How relevant are ACOG and SGO guidelines for referral of adnexal mass? Obstet Gynecol 2007;110:841-8.
14. Ueland FR, Desimone CP, Seamon LG, Miller RA, Goodrich S, Podzielinski I, et al. Effectiveness of multivariate index assay in the preoperative assessment of ovarian tumors. Obstet Gynecol 2011;117:1289-97.
15. Miller RW, Smith A, DeSimone CP, Seamon LG, Goodrich S, Podzielinski I, et al. Performance of the American College of Obstetricians and Gynecologists' ovarian tumor referral guidelines with a multivariate index assay. Obstet Gynecol 2011;117:1298-306.
16. Moore RG, Miller MC, Disilvestro P, Landrum LM, Gajewski W, Ball JJ, et al. Evaluation of the diagnostic accuracy of the risk of ovarian malignancy algorithm in women with a pelvic mass. Obstet Gynecol 2011;118:280-8.
17. Jacobs I, Oram D, Fairbanks J, Turner J, Frost C, Grudzinskas JG. A risk of malignancy index incorporation CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. BJOG 1990;97:922-9.
18. Asif N, Sattar A, Dawood MM, Rafi T, Aamir M, Anwar M. Pre-operative evaluation of ovarian mass: risk of malignancy index. J Coll Physicians Surg Pak 2004;14:128-31.
19. Davies AP, Jacobs I, Woolas R, Fish A, Oram D. The adnexal mass: benign or malignant? Evaluation of a risk of malignancy index. BJOG 1993;100:927-31.
20. Obeidat BR, Amarin ZO, Latimer JA, Crawford RA. Risk of malignancy index in the preoperative evaluation of pelvic masses. Int J Gynaecol Obstet 2004;85:255-8.
21. Lu C, Van Gestel T, Suykens JA, VanHuffel S, Vergote I, Timmerman D. Preoperative prediction of malignancy of ovarian tumors using least squares support vector machines. Artif Intell Med 2003;28:281-306.
22. Manjunath AP, Pratapkumar, Sujatha K, Vani R. Comparison of three risk of malignancy indices in evaluation of pelvic masses. Gynecol Oncol 2001;81:225-9.
23. Tingulstad S, Hagen B, Skjeldestad FE, Onsrud M, Kiserud T, Halvorsent T, et al. Evaluation of a risk of malignancy index based on serum CA 125, ultrasound findings and menopausal status in the pre-operative diagnosis of pelvic masses. BJOG 1996;103:826-31.
24. Timmerman D, Bourne TH, Tailor A, Collins WP, Verrelst H, Vandenberghe K, et al. A comparison of methods for preoperative discrimination between malignant and benign adnexal masses: the development of a new logistic regression model. Am J Obstet Gynecol 1999;181:57-65.